{"id":"https://openalex.org/W2891292960","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20647","title":"Association of high circulating neuregulin-1 with clinical benefit in EGFR wild-type NSCLC patients treated with rilotumumab and erlotinib.","display_name":"Association of high circulating neuregulin-1 with clinical benefit in EGFR wild-type NSCLC patients treated with rilotumumab and erlotinib.","publication_year":2016,"publication_date":"2016-05-20","ids":{"openalex":"https://openalex.org/W2891292960","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20647","mag":"2891292960"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.34.15_suppl.e20647","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20647","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20647","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037741567","display_name":"Laura P. Stabile","orcid":"https://orcid.org/0000-0002-1822-2707","observed_orcids":["https://orcid.org/0000-0002-1822-2707"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura P. Stabile","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA;","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020955148","display_name":"Ahmad A. Tarhini","orcid":"https://orcid.org/0000-0002-3193-9702","observed_orcids":["https://orcid.org/0000-0002-3193-9702"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ahmad A. Tarhini","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA;","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007506465","display_name":"Mariya Farooqui","orcid":"https://orcid.org/0000-0002-2136-8694","observed_orcids":["https://orcid.org/0000-0002-2136-8694"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mariya Farooqui","raw_affiliation_strings":["University of Minnesota, Minneapolis, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Minnesota, Minneapolis, MN;","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110692508","display_name":"Jos\u00e9 G\u00f3mez-Garc\u00eda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jose Gomez-Garcia","raw_affiliation_strings":["University of Minnesota, Minneapolis, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Minnesota, Minneapolis, MN;","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022124144","display_name":"Autumn Gaither\u2010Davis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Autumn Gaither-Davis","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA;","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017526826","display_name":"William E. Gooding","orcid":"https://orcid.org/0000-0001-9070-3559","observed_orcids":["https://orcid.org/0000-0001-9070-3559"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William E. Gooding","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA;","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. Socinski","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA;","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031746829","display_name":"Jill M. Siegfried","orcid":"https://orcid.org/0000-0002-0887-5448","observed_orcids":["https://orcid.org/0000-0002-0887-5448"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jill M. Siegfried","raw_affiliation_strings":["University of Minnesota, Minneapolis, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Minnesota, Minneapolis, MN;","institution_ids":["https://openalex.org/I130238516"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"15_suppl","first_page":"e20647","last_page":"e20647"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neuregulin-1","display_name":"neuregulin-1","score":0.996999979019165},{"id":"https://openalex.org/keywords/rilotumumab","display_name":"rilotumumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/circulating-biomarkers","display_name":"circulating biomarkers","score":0.9259999990463257},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.6830000281333923},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8679999709129333},{"id":"https://openalex.org/keywords/amphiregulin","display_name":"amphiregulin","score":0.9319999814033508},{"id":"https://openalex.org/keywords/transforming-growth-factor-alpha","display_name":"transforming growth factor-alpha","score":0.7630000114440918},{"id":"https://openalex.org/keywords/heparin-binding-egf","display_name":"heparin-binding EGF","score":0.8700000047683716},{"id":"https://openalex.org/keywords/met-signaling","display_name":"C-MET signaling","score":0.7760000228881836},{"id":"https://openalex.org/keywords/her3-signaling","display_name":"HER3 signaling","score":0.7179999947547913},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.871999979019165}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8622854948043823},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.831916093826294},{"id":"https://openalex.org/C2780806702","wikidata":"https://www.wikidata.org/wiki/Q14866198","display_name":"Amphiregulin","level":4,"score":0.6660205125808716},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6395881175994873},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5351423025131226},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.5103446841239929},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5082271099090576},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.44788122177124023},{"id":"https://openalex.org/C2778560701","wikidata":"https://www.wikidata.org/wiki/Q14914188","display_name":"Neuregulin 1","level":3,"score":0.42182135581970215},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3717249035835266},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.26604360342025757},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.15065690875053406}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2016.34.15_suppl.e20647","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20647","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.e20647","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2610255173","https://openalex.org/W2793173935","https://openalex.org/W2291389467","https://openalex.org/W2569928833","https://openalex.org/W2996164267","https://openalex.org/W2977460126","https://openalex.org/W2600507120","https://openalex.org/W2603396766","https://openalex.org/W2607278979","https://openalex.org/W2014230197"],"abstract_inverted_index":{"e20647":[0],"Background:":[1],"We":[2,92,140],"previously":[3,40],"reported":[4],"a":[5,16,218,242],"59%":[6],"disease":[7,54],"control":[8],"rate":[9,173],"among":[10,56,109],"EGFR":[11,32,59,66,100,120,123,129,223,250],"wild-type":[12],"(WT)":[13],"patients":[14,37,51,79],"in":[15,36,81],"phase":[17],"II":[18],"trial":[19,111],"of":[20,23,88,145,156,244],"the":[21,82,99],"combination":[22],"rilotumumab":[24],"(an":[25,31],"HGF":[26],"neutralizing":[27],"antibody)":[28],"and":[29,49,101,137,151,162,180,201,231,251],"erlotinib":[30],"tyrosine":[33],"kinase":[34],"inhibitor)":[35],"with":[38,52,98,106,167,170,182,211,229],"metastatic":[39],"treated":[41],"NSCLC.":[42],"There":[43,62],"was":[44,75,116,178],"1":[45,71,122],"partial":[46],"response":[47],"(PR)":[48],"16":[50],"stable":[53],"(SD)":[55],"29":[57],"confirmed":[58,65],"WT":[60],"cases.":[61],"were":[63,209],"two":[64],"mutant":[67],"cases":[68],"(1":[69],"PR,":[70],"SD).":[72],"Baseline":[73,154],"plasma":[74,143],"collected":[76],"from":[77,248],"35":[78,110],"enrolled":[80],"study":[83],"to":[84,274],"identify":[85],"potential":[86],"biomarkers":[87,96],"treatment":[89],"response.":[90],"Methods:":[91],"examined":[93],"10":[94],"circulating":[95],"associated":[97,181,210],"c-Met":[102,276],"pathways":[103],"for":[104,113,220],"association":[105],"clinical":[107],"benefit":[108],"participants":[112],"whom":[114],"blood":[115],"successfully":[117],"processed":[118],"(31":[119],"WT,":[121],"mutant).":[124],"Biomarkers":[125],"measured":[126,142],"included":[127],"4":[128],"ligands:":[130],"amphiregulin":[131],"(AREG),":[132],"heparin-binding":[133],"EGF":[134],"(HB-EGF),":[135],"TGF\u03b1,":[136],"neuregulin-1":[138],"(NRG1).":[139],"also":[141,232],"levels":[144,155],"soluble":[146],"c-Met,":[147],"HGF,":[148],"VEGF,":[149],"IL6":[150],"IL8.":[152],"Results:":[153],"four":[157],"proteins":[158],"(AREG,":[159],"IL6,":[160],"NRG1,":[161],"TGF\u03b1)":[163],"showed":[164],"significant":[165],"associations":[166],"progression-free":[168],"survival,":[169],"false":[171],"discovery":[172],"<":[174],"10%":[175],"High":[176],"NRG1":[177,216],"protective":[179],"longer":[183],"PFS":[184],"(HR":[185,195,203],"=":[186,190,196,199,204,207],"0.41,":[187],"95%":[188],"CI":[189,198,206],".19-.87),":[191],"while":[192],"high":[193],"AREG":[194],"2.14,":[197],"1.48-3.08)":[200],"TGF\u03b1":[202],"1.77,":[205],"1.01-3.11)":[208],"more":[212,245,263,270],"rapid":[213],"progression.":[214],"Conclusions:":[215],"is":[217],"ligand":[219],"HER3,":[221],"an":[222],"family":[224],"member":[225],"that":[226,255],"often":[227],"dimerizes":[228],"EGFR/HER1,":[230],"can":[233],"be":[234,262],"activated":[235],"by":[236],"c-Met.":[237,252],"HER3":[238,258,273],"may":[239,261],"serve":[240],"as":[241],"mediator":[243],"prolonged":[246],"signaling":[247,260],"both":[249],"NSCLC":[253],"tumors":[254],"show":[256],"elevated":[257],"pathway":[259],"dependent":[264,271],"on":[265,272],"EGFR-c-Met":[266],"cross":[267],"talk":[268],"and/or":[269],"propagate":[275],"signaling.":[277]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2018-09-27T00:00:00"}